Aptose Biosciences (NASDAQ:APTO) Price Target Cut to $2.00 by Analysts at HC Wainwright

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) had its price objective decreased by HC Wainwright from $7.00 to $2.00 in a research report report published on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Separately, StockNews.com started coverage on shares of Aptose Biosciences in a research note on Wednesday, November 13th. They issued a “hold” rating on the stock.

Aptose Biosciences Price Performance

APTO opened at $0.19 on Wednesday. The company’s 50 day simple moving average is $0.38 and its two-hundred day simple moving average is $0.61. Aptose Biosciences has a 1-year low of $0.13 and a 1-year high of $2.91. The firm has a market capitalization of $3.44 million, a price-to-earnings ratio of -0.05 and a beta of 1.26.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp grew its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the period. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.